Handok

Handok Debt

The Debt of Handok (002390.KS) as of Nov 4, 2026 is 80.51 B KRW. In the previous year, Debt was 142.91 B KRW — a change of -43.67% (lower).

Debt

80.51 BKRW

YoY

-43.67%

Last updated:

In 2025, Handok's total debt was 80.51 B KRW, a -43.67% change from the 142.91 B KRW total debt recorded in the previous year.

The Handok Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
158.43 B KRW
Jan 1, 2019
213.65 B KRW
Jan 1, 2020
152.85 B KRW
Jan 1, 2021
138.79 B KRW
Jan 1, 2022
184.69 B KRW
Jan 1, 2023
123.78 B KRW
Jan 1, 2024
142.91 B KRW
Jan 1, 2025
80.51 B KRW
The Handok Debt history
YEARDebtYoY
80.51 BKRW-43.67%
142.91 BKRW+15.46%
123.78 BKRW-32.98%
184.69 BKRW+33.08%
138.79 BKRW-9.20%
152.85 BKRW-28.46%
213.65 BKRW+34.86%
158.43 BKRW-16.16%
188.95 BKRW+12.72%
167.63 BKRW+8.15%
154.99 BKRW+8.35%
143.05 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Handok Stock analysis

What does Handok do? Handok, Inc. generates revenue through the manufacture and sale of pharmaceutical products including Amaryl for diabetes, Tritace for hypertension and cardiovascular diseases, Teveten and Triapin for hypertension, Munobal for hypertension and stenocardia, Ketas for cerebral circulation issues, and Lasix for hypertension and edema. The company also sells over-the-counter pharmaceuticals, healthcare products, medical devices, diagnostic reagents, and vaccines. Additionally, Handok, Inc. earns income from real estate rental services. Its products target healthcare providers, hospitals, and pharmacies as key buyers within the pharmaceutical and healthcare sectors. The firm's product portfolio includes branded medications such as Amaryl, Tritace, Teveten, Triapin, Munobal, Ketas, and Lasix, which are distributed to medical professionals and retail pharmacies. Over-the-counter products and healthcare items are sold directly to consumers through retail channels. Medical devices and diagnostic reagents are supplied to healthcare facilities and laboratories. Vaccines are distributed to public health institutions and clinics. Handok, Inc. serves multiple market segments including diabetes management, cardiovascular care, hypertension treatment, and neurological health through its diverse product range. The company's real estate rental business supports its financial operations by providing steady income streams from leased properties. Key buyers include healthcare providers, pharmacies, hospitals, and public health institutions that purchase its branded pharmaceuticals and medical solutions. Handok is one of the most popular companies on Eulerpool.

Debt Details

Understanding Handok's Debt Structure

Handok's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Handok's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Handok’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Handok’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Handok stock

Debt of Handok is 80.51 B KRW in 2025.

Debt of Handok changed from 142.91 B KRW to 80.51 B KRW, representing a -43.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Handok since 2006 – with annual values, charts, and detailed analysis.

Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Handok historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Handok

All Key Metrics — Handok